Eur Rev Med Pharmacol Sci 2019; 23 (11): 4656-4662

DOI: 10.26355/eurrev_201906_18045

Clinical significance of lncRNA FAM83H-AS1 in ovarian cancer

Y.-B. Gong, Y.-F. Zou

Department of Obstetrics and Gynecology, Hanchuan People’s Hospital, Hanchuan, China. fenfenzou2011@163.com


OBJECTIVE: The aim of this study was to explore the expression of long non-coding RNA (lncRNA) FAM83H-AS1 and its clinical significance in ovarian cancer (OC).

PATIENTS AND METHODS: Quantitative Real Time-Polymerase Chain Reaction (qRT-PCR) was performed to examine the expression level of lncRNA FAM83H-AS1 in 100 pairs of OC tissues and para-cancerous specimens. Meanwhile, the relationship between lncRNA FAM83H-AS1 expression and clinical features of OC patients was analyzed. According to the mean expression level of lncRNA FAM83H-AS1 (3.693), OC patients were divided into two groups, including the high-expression group (n=48) and low-expression group (n=52). After that, the association between lncRNA FAM83H-AS1 expression and clinicopathological features of OC patients was analyzed. Moreover, the correlation between the expression level of lncRNA FAM83H-AS1 and the survival time of patients was estimated using the Kaplan-Meier method. After OVCAR-3 cells were transfected with Si-FAM83H-AS1 or si-NC, the expression of FAM83H-AS1 in OVCAR-3 cells was detected by qRT-PCR.

RESULTS: First, qRT-PCR was used to detect the expression of lncRNA FAM83H-AS1 in OC tissues and cell lines. The results showed that lncRNA FAM83H-AS1 was significantly up-regulated in both OC tissues and OC cells when compared with normal controls. Meanwhile, lncRNA FAM83H-AS1 expression was correlated with tumor pathological grade, FIGO stage and distant metastasis of OC patients. Survival analysis was performed by the Kaplan-Meier method. The results indicated that the overall survival time of patients with higher lncRNA FAM83H-AS1 expression was markedly shorter than those with lower lncRNA FAM83H-AS1 expression. In addition, down-regulation of lncRNA FAM83H-AS1 by si-FAM83H-AS1 transfection could remarkably inhibit proliferation and invasion of OC cells in vitro.

CONCLUSIONS: LncRNA FAM83H-AS1 was a novel factor involved in OC progression. Our findings suggested that FAM83H-AS1 could serve as a potential biomarker and therapeutic target for OC.

Free PDF Download

To cite this article

Y.-B. Gong, Y.-F. Zou
Clinical significance of lncRNA FAM83H-AS1 in ovarian cancer

Eur Rev Med Pharmacol Sci
Year: 2019
Vol. 23 - N. 11
Pages: 4656-4662
DOI: 10.26355/eurrev_201906_18045